These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 9069162)

  • 41. Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.
    Liu JL; Zhu HM; Huang QR; Zhang ZL; Li HL; Qin YJ; Zhang Y; Wei DL; Lu JH; Liu H; Chen XP; Liu YJ; Ekangaki A; Zheng YM; Diez-Perez A; Harper K
    Chin Med J (Engl); 2004 Jul; 117(7):1029-35. PubMed ID: 15265377
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vertebral body index and bone mineral density in women with spinal fractures. 66 probands compared with controls.
    Goh JC; Low SL; Bose K
    Acta Orthop Scand; 1994 Oct; 65(5):522-4. PubMed ID: 7801754
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of denosumab on trabecular bone score in postmenopausal women with osteoporosis.
    McClung MR; Lippuner K; Brandi ML; Zanchetta JR; Bone HG; Chapurlat R; Hans D; Wang A; Zapalowski C; Libanati C
    Osteoporos Int; 2017 Oct; 28(10):2967-2973. PubMed ID: 28748386
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.
    Seibel MJ; Naganathan V; Barton I; Grauer A
    J Bone Miner Res; 2004 Feb; 19(2):323-9. PubMed ID: 14969403
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Longitudinal changes of bone mineral density and bone turnover in postmenopausal women on thyroxine.
    Guo CY; Weetman AP; Eastell R
    Clin Endocrinol (Oxf); 1997 Mar; 46(3):301-7. PubMed ID: 9156039
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risedronate decreases bone resorption and improves low back pain in postmenopausal osteoporosis patients without vertebral fractures.
    Ohtori S; Akazawa T; Murata Y; Kinoshita T; Yamashita M; Nakagawa K; Inoue G; Nakamura J; Orita S; Ochiai N; Kishida S; Takaso M; Eguchi Y; Yamauchi K; Suzuki M; Aoki Y; Takahashi K
    J Clin Neurosci; 2010 Feb; 17(2):209-13. PubMed ID: 20044258
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The levels of bone turnover markers in Chinese postmenopausal women: Peking Vertebral Fracture study.
    Zhao J; Xia W; Nie M; Zheng X; Wang Q; Wang X; Wang W; Ning Z; Huang W; Jiang Y; Li M; Wang O; Xing X; Sun Y; Luo L; He S; Yu W; Lin Q; Pei Y; Zhang F; Han Y; Tong Y; Che Y; Shen R; Hu Y; Zhou X; Xu L
    Menopause; 2011 Nov; 18(11):1237-43. PubMed ID: 21747303
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Plasma leptin concentrations are associated with bone mineral density and the presence of vertebral fractures in postmenopausal women.
    Yamauchi M; Sugimoto T; Yamaguchi T; Nakaoka D; Kanzawa M; Yano S; Ozuru R; Sugishita T; Chihara K
    Clin Endocrinol (Oxf); 2001 Sep; 55(3):341-7. PubMed ID: 11589677
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.
    Liberman UA; Weiss SR; Bröll J; Minne HW; Quan H; Bell NH; Rodriguez-Portales J; Downs RW; Dequeker J; Favus M
    N Engl J Med; 1995 Nov; 333(22):1437-43. PubMed ID: 7477143
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The value of osteopontin in the assessment of bone mineral density status in postmenopausal women.
    Fodor D; Bondor C; Albu A; Simon SP; Craciun A; Muntean L
    J Investig Med; 2013 Jan; 61(1):15-21. PubMed ID: 23117696
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Bone material strength is associated with areal BMD but not with prevalent fractures in older women.
    Rudäng R; Zoulakis M; Sundh D; Brisby H; Diez-Perez A; Johansson L; Mellström D; Darelid A; Lorentzon M
    Osteoporos Int; 2016 Apr; 27(4):1585-1592. PubMed ID: 26630975
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis.
    Iwamoto J; Takeda T; Sato Y; Uzawa M
    Yonsei Med J; 2004 Aug; 45(4):676-82. PubMed ID: 15344210
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The distal radial fracture in elderly women and the bone mineral density of the lumbar spine and hip.
    Hegeman JH; Oskam J; van der Palen J; Ten Duis HJ; Vierhout PA
    J Hand Surg Br; 2004 Oct; 29(5):473-6. PubMed ID: 15336753
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture.
    Kanis JA; Barton IP; Johnell O
    Osteoporos Int; 2005 May; 16(5):475-82. PubMed ID: 15875093
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis.
    Thiébaud D; Burckhardt P; Kriegbaum H; Huss H; Mulder H; Juttmann JR; Schöter KH
    Am J Med; 1997 Oct; 103(4):298-307. PubMed ID: 9382122
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Comparison of effect of treatment with etidronate and alendronate on lumbar bone mineral density in elderly women with osteoporosis.
    Iwamoto J; Takeda T; Sato Y; Uzawa M
    Yonsei Med J; 2005 Dec; 46(6):750-8. PubMed ID: 16385649
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast.
    Tankó LB; McClung MR; Schimmer RC; Mahoney P; Christiansen C
    Bone; 2003 Apr; 32(4):421-6. PubMed ID: 12689686
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vertebral fracture prevalence among Greek healthy middle-aged postmenopausal women: association with demographics, anthropometric parameters, and bone mineral density.
    Lambrinoudaki I; Flokatoula M; Armeni E; Pliatsika P; Augoulea A; Antoniou A; Alexandrou A; Creatsa M; Panoulis C; Dendrinos S; Papacharalambous X
    Spine J; 2015 Jan; 15(1):86-94. PubMed ID: 25106754
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Design for an ipriflavone multicenter European fracture study.
    Reginster JY; Bufalino L; Christiansen C; Devogelaer JP; Gennari C; Riis BJ; Roux C
    Calcif Tissue Int; 1997; 61 Suppl 1():S28-32. PubMed ID: 9263614
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of recombinant human parathyroid hormone (1-84) on vertebral fracture and bone mineral density in postmenopausal women with osteoporosis: a randomized trial.
    Greenspan SL; Bone HG; Ettinger MP; Hanley DA; Lindsay R; Zanchetta JR; Blosch CM; Mathisen AL; Morris SA; Marriott TB;
    Ann Intern Med; 2007 Mar; 146(5):326-39. PubMed ID: 17339618
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.